|
Periodicals
|
A Colorado… A Colorado mass-vaccination site was closed Wednesday after 11 people experienced adverse effects after being given a shot of the Johnson & Johnson Covid-19 vaccine, The Wall Street Journal's Talal Ansari reports. "Medical staff on site determined two individuals required additional observation and out of an abundance of caution, they were transported to a nearby hospital," Centura Health, which runs the site along with the state of Colorado, said in a statement. It is unclear whether the adverse reactions were related to the vaccine. Reference Link ShowHide Related Items >><< - 04/05/21
- Cidara, Janssen enter agreement to develop, commercialize AVCs
- 04/05/21
- J&J assumes responsibility of vaccine manufacturing at Emergent facility
- 04/05/21
- Emergent BioSolutions receives modified $23M task order from BARDA
- 04/01/21
- SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study
- 04/01/21 Piper Sandler
- Integra to benefit from FDA safety communication, says Piper Sandler
- 02/10/21 BTIG
- Model N upgraded to Buy from Neutral at BTIG
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 02/01/21 Wells Fargo
- Moderna price target raised to $145 from $129 at Wells Fargo
- 01/26/21
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 01/26/21
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- 04/08/21
- Official warned that Emergent plant had to be 'monitored closely,' NYT reports
- 04/06/21
- Biden to say all U.S. adults should be vaccine-eligible by April 19, WSJ says
- 04/06/21
- Emergent BioSolutions plant flouted rules, downplayed errors, NY Times reports
- 04/05/21
- Biden administration aims to help AstraZeneca find U.S. facility, Reuters says
- 04/05/21
- Fly Intel: Wall Street's top stories for Monday
- 04/05/21
- Fly Intel: Wall Street's top stories at midday
- 04/01/21
- Fly Intel: Wall Street's top stories for Thursday
- 04/01/21
- Fly Intel: Wall Street's top stories at midday
- 04/01/21
- Unusually active option classes on open April 1st
- 03/01/21
- Unusually active option classes on open March 1st
- 01/26/21
- Early notable gainers among liquid option names on January 26th
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
|
|
Conference/Events
|
Biopharma Analysts Chen… Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm. ShowHide Related Items >><< - 03/04/21
- VYNE Therapeutics expects cash to fund requirements through end of 2022
- 03/01/21
- VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3
- 02/11/21
- VYNE Therapeutics approves 1-for-4 reverse stock split
- 02/01/21
- VYNE Therapeutics' Amzeeq label update approved by FDA
- 04/01/21
- FDA approves Praluent as on add-on therapy for adult patients with HoFH
- 03/30/21
- NIH trial finds Regeneron's Eylea reduced vision-threatening complications
- 03/23/21
- Regeneron: Phase 3 REGEN-COV trial met primary, secondary endpoints
- 03/15/21
- Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit
- 03/02/21
- BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne
- 02/02/21
- BiomX announces 'positive' results from Phase 1a pharmacokinetic study of BX002
- 11/04/20
- BiomX doses first subject in Phase 1a study of BX002 for inflammatory bowel
- 04/07/21
- U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions
- 04/07/21
- Pfizer's NDA for abrocitinib in dermatitis granted extended review by FDA
- 04/06/21
- Cogent Biosciences names John Robinson, PhD as Chief Scientific Officer
- 04/01/21
- Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study
- 04/08/21
- Eli Lilly, Incyte announce baricitinib study did not meet primary endpoint
- 04/07/21
- Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly
- 04/06/21
- Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period
- 04/01/21
- Fortress Biotech partner Journey Medical to acquire QBREXA from Dermira
- 04/05/21
- Cidara, Janssen enter agreement to develop, commercialize AVCs
- 04/05/21
- J&J assumes responsibility of vaccine manufacturing at Emergent facility
- 04/05/21
- Emergent BioSolutions receives modified $23M task order from BARDA
- 04/01/21
- SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study
- 03/29/21
- Incyte announces European Commission approval of Pemazyre
- 03/23/21
- Incyte reports approval of Pemazyre in Japan for BTC with FGFR2 gene
- 04/08/21
- Bristol-Myers reports 'positive' results from Phase 3 CheckMate -648 trial
- 04/01/21
- Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers
- 03/30/21
- Huyabio International enters clinical collaboration agreement with Bristol-Myers
- 03/29/21
- EMA validates Bristol-Myers' Opdivo application in Muscle-Invasive Carcinoma
ARQT Arcutis Biotherapeutics - 03/26/21
- Arcutis Biotherapeutics announces updates to its executive team
- 03/18/21
- Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252
- 03/17/21
- Arcutis Biotherapeutics to present outcomomes, data, on roflumilast 0.3% cream
- 02/18/21
- Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff
ACRS Aclaris Therapeutics - 03/15/21
- Aclaris Therapeutics completes enrollment in Phase 2a ATI-1777 trial
- 02/25/21
- Aclaris Therapeutics sees cash, equivalents funding operations through 2023E
- 02/22/21
- Aclaris Therapeutics trading resumes
- 02/22/21
- Aclaris Therapeutics trading halted, volatility trading pause
- 03/24/21 Canaccord
- Regeneron trial shows positive results against COVID-variants, says Canaccord
- 03/23/21 Piper Sandler
- Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
- 03/11/21 Evercore ISI
- Kodiak Sciences initiated with an Outperform at Evercore ISI
- 03/11/21 Needham
- Vir Biotechnology price target raised to $80 from $75 at Needham
- 04/06/21 JPMorgan
- JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
- 03/24/21 BMO Capital
- AbCellera price target lowered to $59 from $61 at BMO Capital
- 03/17/21 Mizuho
- AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
- 03/16/21 Mizuho
- Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
- 03/08/21 BofA
- Gartner added to US 1 List, Bristol-Myers removed at BofA
- 02/12/21 Morgan Stanley
- Amgen court decision may have readthrough for Gilead, says Morgan Stanley
- 02/02/21 BTIG
- Prothena upgraded to Buy at BTIG on birtamimab 'revival'
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 04/06/21 RBC Capital
- Pfizer transferred with a Sector Perform at RBC Capital
- 02/23/21 B. Riley
- B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
- 02/10/21 KeyBanc
- Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
- 04/01/21 Piper Sandler
- Integra to benefit from FDA safety communication, says Piper Sandler
- 02/10/21 BTIG
- Model N upgraded to Buy from Neutral at BTIG
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 02/01/21 Wells Fargo
- Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics - 02/02/21 Truist
- Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
- 02/01/21 Cowen
- Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
- 01/28/21 JonesTrading
- Arcutis Biotherapeutics initiated with a Buy at JonesTrading
- 11/09/20 Goldman Sachs
- Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
- 02/10/21 SVB Leerink
- Incyte downgraded to Market Perform from Outperform at SVB Leerink
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/04/21 Guggenheim
- Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics - 03/04/21 SVB Leerink
- Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
- 02/02/21 Cantor Fitzgerald
- Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
- 01/19/21 William Blair
- Aclaris has potential in range of 'blockbuster indications,' says William Blair
- 02/02/21 H.C. Wainwright
- BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
- 12/07/20 H.C. Wainwright
- BiomX initiated with a Buy at H.C. Wainwright
- 10/05/20 H.C. Wainwright
- VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
- 03/04/21
- VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c)
- 11/05/20
- VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c)
- 02/05/21
- Regeneron reports Q4 EPS $9.53, consensus $8.39
- 02/04/21
- Notable companies reporting before tomorrow's open
- 11/05/20
- Regeneron reports Q3 EPS $8.36, consensus $7.13
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 01/29/21
- Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20
- 01/29/21
- Eli Lilly reports Q4 EPS $2.75, consensus $2.35
- 01/28/21
- Notable companies reporting before tomorrow's open
- 01/26/21
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 01/26/21
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- 02/09/21
- Incyte reports Q4 EPS 93c, consensus 75c
- 02/08/21
- Notable companies reporting before tomorrow's open
- 11/05/20
- Incyte reports Q3 EPS 23c, consensus 75c
- 03/04/21
- Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c)
- 02/24/21
- CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M
- 02/04/21
- Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45
- 02/04/21
- Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41
ARQT Arcutis Biotherapeutics - 02/16/21
- Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c)
- 11/05/20
- Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c)
ACRS Aclaris Therapeutics - 02/25/21
- Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c)
- 11/04/20
- Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)
|
|
Periodicals
|
A top federal pandemic… A top federal pandemic official warned last June that Emergent BioSolutions (EBS), which recently threw out millions of doses of Covid-19 vaccines because of contamination, lacked enough trained staff and had a record of problems with quality control, The New York Times' Sheryl Gay Stolberg, Sharon LaFraniere and Chris Hamby report. The report, which was written by Carlo de Notaristefani, a manufacturing expert who has overseen production of Covid-19 vaccines for the federal government since last May, cited "key risks" in relying on Emergent to handle the production of vaccines developed by both Johnson & Johnson (JNJ) and AstraZeneca (AZN) at Emergent's Baltimore plant. Addressing the problems "will require significant effort," and the company "will have to be monitored closely," the official said in the report. Reference Link ShowHide Related Items >><< - 04/05/21
- Cidara, Janssen enter agreement to develop, commercialize AVCs
- 04/01/21
- SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study
EBS Emergent BioSolutions - 04/05/21
- J&J assumes responsibility of vaccine manufacturing at Emergent facility
- 04/05/21
- Emergent BioSolutions receives modified $23M task order from BARDA
- 04/02/21
- Emergent says treatment for hospitalized Covid patients shows no benefit
- 04/02/21
- Emergent BioSolutions says 'disappointed' by COVID-HIG trial topline data
- 04/07/21
- MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots
- 04/07/21
- U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions
- 04/07/21
- EMA concludes blood clots 'very rare' side effect of Astra vaccine
EBS Emergent BioSolutions - 04/07/21
- Fly Intel: Top five analyst initiations
- 04/07/21 Benchmark
- Benchmark starts Emergent at Buy, thinks shares can resume upward momentum
- 04/07/21 Benchmark
- Emergent BioSolutions initiated with a Buy at Benchmark
- 02/24/21 Chardan
- Chardan reverses last week's downgrade, upgrades Emergent to Buy
- 04/01/21 Piper Sandler
- Integra to benefit from FDA safety communication, says Piper Sandler
- 02/10/21 BTIG
- Model N upgraded to Buy from Neutral at BTIG
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 02/01/21 Wells Fargo
- Moderna price target raised to $145 from $129 at Wells Fargo
- 04/07/21 Citi
- FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
- 03/26/21 Piper Sandler
- AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
- 03/23/21 Societe Generale
- AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
- 03/18/21 Deutsche Bank
- AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
- 01/26/21
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 01/26/21
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
EBS Emergent BioSolutions - 04/05/21
- Emergent BioSolutions backs FY21 revenue view $1.95B-$2.05B, consensus $2.02B
- 02/18/21
- Emergent BioSolutions sees FY21 revenue $1.95B-$2.05B, consensus $1.93B
- 02/18/21
- Emergent BioSolutions reports Q4 adjusted EPS $3.67, consensus $3.19
- 01/10/21
- Emergent BioSolutions sees FY20 revenue $1.55B-$1.56B, consensus $1.53B
- 04/07/21
- EMA says benefits of AstraZeneca Covid vaccine outweigh side effects
- 02/11/21
- AstraZeneca sees FY21 core EPS $4.75-$5.00
- 02/11/21
- AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 04/06/21
- Biden to say all U.S. adults should be vaccine-eligible by April 19, WSJ says
- 04/04/21
- J&J COVID vaccine emerges as preferred shot for homeless, WSJ says
EBS Emergent BioSolutions - 04/06/21
- Emergent BioSolutions plant flouted rules, downplayed errors, NY Times reports
- 04/05/21
- Biden administration aims to help AstraZeneca find U.S. facility, Reuters says
- 03/31/21
- 15M doses of J&J's COVID vaccine ruined by mix up at plant, NY Times reports
- 03/08/21
- Biden to meet with CEOs of J&J, Merck at White House, Reuters reports
- 04/07/21
- Italy recommends AstraZeneca vaccine only for over-60s, Reuters reports
- 04/07/21
- Italy recommends Astra COVID vaccine use for over 60 years old, Bloomberg says
- 04/06/21
- Oxford halts dosing in AstraZeneca vaccine trial in children, teens, WSJ says
EBS Emergent BioSolutions - 04/05/21
- Fly Intel: Wall Street's top stories for Monday
- 04/05/21
- Fly Intel: Wall Street's top stories at midday
- 04/01/21
- Fly Intel: Wall Street's top stories for Thursday
- 04/01/21
- Fly Intel: Wall Street's top stories at midday
- 04/07/21
- Fly Intel: Wall Street's top stories for Wednesday
- 04/07/21
- FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill
- 04/01/21
- Unusually active option classes on open April 1st
- 03/01/21
- Unusually active option classes on open March 1st
- 01/26/21
- Early notable gainers among liquid option names on January 26th
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 04/01/21
- AstraZeneca put volume heavy and directionally bearish
- 03/22/21
- AstraZeneca call volume above normal and directionally bullish
- 03/16/21
- Unusually active option classes on open March 16th
- 02/24/21
- AstraZeneca call volume above normal and directionally bullish
|
|
Conference/Events
|
Biopharma Analysts Chen… Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm. ShowHide Related Items >><< - 03/04/21
- VYNE Therapeutics expects cash to fund requirements through end of 2022
- 03/01/21
- VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3
- 02/11/21
- VYNE Therapeutics approves 1-for-4 reverse stock split
- 02/01/21
- VYNE Therapeutics' Amzeeq label update approved by FDA
- 04/01/21
- FDA approves Praluent as on add-on therapy for adult patients with HoFH
- 03/30/21
- NIH trial finds Regeneron's Eylea reduced vision-threatening complications
- 03/23/21
- Regeneron: Phase 3 REGEN-COV trial met primary, secondary endpoints
- 03/15/21
- Regeneron, Sanofi announce Libtayo study to be stopped early due to OS benefit
- 03/02/21
- BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne
- 02/02/21
- BiomX announces 'positive' results from Phase 1a pharmacokinetic study of BX002
- 11/04/20
- BiomX doses first subject in Phase 1a study of BX002 for inflammatory bowel
- 04/07/21
- U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions
- 04/07/21
- Pfizer's NDA for abrocitinib in dermatitis granted extended review by FDA
- 04/06/21
- Cogent Biosciences names John Robinson, PhD as Chief Scientific Officer
- 04/01/21
- Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study
- 04/07/21
- Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly
- 04/06/21
- Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period
- 04/01/21
- Fortress Biotech partner Journey Medical to acquire QBREXA from Dermira
- 03/29/21
- Eli Lilly, Vir, GSK announces topline data from Phase 2 BLAZE-4 trial
- 04/05/21
- Cidara, Janssen enter agreement to develop, commercialize AVCs
- 04/05/21
- J&J assumes responsibility of vaccine manufacturing at Emergent facility
- 04/05/21
- Emergent BioSolutions receives modified $23M task order from BARDA
- 04/01/21
- SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study
- 03/29/21
- Incyte announces European Commission approval of Pemazyre
- 03/23/21
- Incyte reports approval of Pemazyre in Japan for BTC with FGFR2 gene
- 03/18/21
- Incyte says DEVENT study of Ruxolitinib did not meet primary endpoint
- 04/01/21
- Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers
- 03/30/21
- Huyabio International enters clinical collaboration agreement with Bristol-Myers
- 03/29/21
- EMA validates Bristol-Myers' Opdivo application in Muscle-Invasive Carcinoma
- 03/28/21
- FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma
ARQT Arcutis Biotherapeutics - 03/26/21
- Arcutis Biotherapeutics announces updates to its executive team
- 03/18/21
- Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252
- 03/17/21
- Arcutis Biotherapeutics to present outcomomes, data, on roflumilast 0.3% cream
- 02/18/21
- Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff
ACRS Aclaris Therapeutics - 03/15/21
- Aclaris Therapeutics completes enrollment in Phase 2a ATI-1777 trial
- 02/25/21
- Aclaris Therapeutics sees cash, equivalents funding operations through 2023E
- 02/22/21
- Aclaris Therapeutics trading resumes
- 02/22/21
- Aclaris Therapeutics trading halted, volatility trading pause
- 03/24/21 Canaccord
- Regeneron trial shows positive results against COVID-variants, says Canaccord
- 03/23/21 Piper Sandler
- Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
- 03/11/21 Evercore ISI
- Kodiak Sciences initiated with an Outperform at Evercore ISI
- 03/11/21 Needham
- Vir Biotechnology price target raised to $80 from $75 at Needham
- 04/06/21 JPMorgan
- JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
- 03/24/21 BMO Capital
- AbCellera price target lowered to $59 from $61 at BMO Capital
- 03/17/21 Mizuho
- AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
- 03/16/21 Mizuho
- Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
- 03/08/21 BofA
- Gartner added to US 1 List, Bristol-Myers removed at BofA
- 02/12/21 Morgan Stanley
- Amgen court decision may have readthrough for Gilead, says Morgan Stanley
- 02/02/21 BTIG
- Prothena upgraded to Buy at BTIG on birtamimab 'revival'
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 04/06/21 RBC Capital
- Pfizer transferred with a Sector Perform at RBC Capital
- 02/23/21 B. Riley
- B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
- 02/10/21 KeyBanc
- Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
- 04/01/21 Piper Sandler
- Integra to benefit from FDA safety communication, says Piper Sandler
- 02/10/21 BTIG
- Model N upgraded to Buy from Neutral at BTIG
- 02/01/21 SVB Leerink
- Moderna price target raised to $80 from $69 at SVB Leerink
- 02/01/21 Wells Fargo
- Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics - 02/02/21 Truist
- Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
- 02/01/21 Cowen
- Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
- 01/28/21 JonesTrading
- Arcutis Biotherapeutics initiated with a Buy at JonesTrading
- 11/09/20 Goldman Sachs
- Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
- 02/10/21 SVB Leerink
- Incyte downgraded to Market Perform from Outperform at SVB Leerink
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/04/21 Guggenheim
- Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics - 03/04/21 SVB Leerink
- Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
- 02/02/21 Cantor Fitzgerald
- Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
- 01/19/21 William Blair
- Aclaris has potential in range of 'blockbuster indications,' says William Blair
- 02/02/21 H.C. Wainwright
- BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
- 12/07/20 H.C. Wainwright
- BiomX initiated with a Buy at H.C. Wainwright
- 10/05/20 H.C. Wainwright
- VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
- 03/04/21
- VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c)
- 11/05/20
- VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c)
- 02/05/21
- Regeneron reports Q4 EPS $9.53, consensus $8.39
- 02/04/21
- Notable companies reporting before tomorrow's open
- 11/05/20
- Regeneron reports Q3 EPS $8.36, consensus $7.13
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19
- 02/02/21
- Pfizer reports Q4 adjusted EPS 42c, consensus 48c
- 02/01/21
- Notable companies reporting before tomorrow's open
- 01/29/21
- Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20
- 01/29/21
- Eli Lilly reports Q4 EPS $2.75, consensus $2.35
- 01/28/21
- Notable companies reporting before tomorrow's open
- 01/26/21
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 01/26/21
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- 02/09/21
- Incyte reports Q4 EPS 93c, consensus 75c
- 02/08/21
- Notable companies reporting before tomorrow's open
- 11/05/20
- Incyte reports Q3 EPS 23c, consensus 75c
- 03/04/21
- Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c)
- 02/24/21
- CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M
- 02/04/21
- Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45
- 02/04/21
- Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41
ARQT Arcutis Biotherapeutics - 02/16/21
- Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c)
- 11/05/20
- Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c)
ACRS Aclaris Therapeutics - 02/25/21
- Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c)
- 11/04/20
- Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)
|